At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients
In Brief
A Phase 2 clinical trial evaluating Anastrozole, Exemestane, and 5 other interventions for Anatomic Stage IV Breast Cancer AJCC v8 and 6 related conditions. Completed, enrolled 36 participants across 10 sites.
Detailed Summary
This phase II trial studies how well radiation therapy given with standard care palbociclib and hormone therapy work in treating patients with breast cancer that has spread from one part of the body to the bone. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Antihormone therapy, such as fulvestrant, letrozole, anastrozole, exemestane, or tamoxifen, may lessen the amount of estrogen made by the body. Giving radiation therapy, palbociclib, and hormone therapy may work better in treating breast cancer patients with bone metastasis.
Study Details
Timeline
Interventions
Given PO
Given PO
Given IM
Given PO
Given PO
Undergo radiation therapy
Given PO